8-K: C4 Therapeutics Advances Cemsidomide, Extends Runway

C4 Therapeutics reports Q2 2025 financial results, highlights positive cemsidomide Phase 1 data in multiple myeloma, and extends cash runway to mid-2027.

Summary

• Reported financial results and business highlights for the second quarter ended June 30, 2025.
• Completed enrollment and dose escalation for the Phase 1 trial of cemsidomide in multiple myeloma (MM) and non-Hodgkin's Lymphoma (NHL).
• Cemsidomide continued to demonstrate a well-tolerated profile and compelling response rates in MM and NHL.
• In the MM cemsidomide plus dexamethasone arm, an overall response rate (ORR) of 40% was observed at the 75g dose level and 50% at the 100g dose level, as of the July 23, 2025, data cutoff date.
• Held a productive Type C meeting with the U.S. Food and Drug Administration (FDA) regarding cemsidomide.
• Expect to align with the FDA on a recommended Phase 2 dose for cemsidomide in MM by year-end 2025.
• Remain on track to initiate registrational development of cemsidomide in early 2026, evaluating it in combination with dexamethasone in late-line MM and with a B-cell maturation antigen bispecific T-cell engager (BCMA BiTE) for earlier lines.
• Prioritizing cemsidomide multiple myeloma registrational development over non-Hodgkin's lymphoma development.
• Achieved a preclinical milestone under the collaboration with Merck KGaA, Darmstadt, Germany, earning $1 million.
• Cash, cash equivalents, and marketable securities totaled $223.0 million as of June 30, 2025.
• The company expects its cash, cash equivalents, and marketable securities to fund its operating plan to mid-2027.
• Partner Betta Pharmaceuticals continues to advance the CFT8919 Phase 1 dose escalation trial in Greater China.
• CFT1946 will not advance beyond the Phase 1 trial, and the company will seek partnership for the BRAF program.

Sentiment

Score: 7

Explanation: The filing presents strong positive clinical data for the lead asset, cemsidomide, with a clear path to registrational trials and extended financial runway. However, increased net losses and a strategic decision to de-prioritize other pipeline assets temper the overall sentiment, indicating a focused but also narrowed internal development strategy.

Positives

• Cemsidomide Phase 1 data in multiple myeloma showed compelling response rates (40% ORR at 75g, 50% ORR at 100g) and a well-tolerated profile.
• Successful Type C meeting with the FDA for cemsidomide, enabling refinement of registrational development plans.
• On track to initiate registrational development of cemsidomide in early 2026, providing a clear path forward for the lead asset.
• Achieved a preclinical milestone with Merck KGaA, earning $1 million, demonstrating progress in collaborations.
• Disciplined capital allocation has extended the cash runway to mid-2027, providing financial stability.
• Clinical evidence of immune T-cell activation with cemsidomide monotherapy supports its potential for enhanced activity in combination with other MM agents.

Negatives

• Total revenue for Q2 2025 decreased to $6.5 million from $12.0 million in Q2 2024, primarily due to an $8.0 million milestone from Biogen in Q2 2024 not recurring.
• Net loss for Q2 2025 increased to $26.0 million from $17.7 million in Q2 2024.
• Net loss per share for Q2 2025 increased to $0.37 from $0.26 in Q2 2024.
• Despite compelling response rates in non-Hodgkin's lymphoma, cemsidomide development is being prioritized for multiple myeloma, potentially delaying or halting its development for NHL patients.
• CFT1946 will not advance beyond Phase 1, and the company will seek a partnership for the BRAF program, indicating a reduction in internally developed pipeline assets.

Risks

• Uncertainties related to the initiation, timing, advancement, and conduct of preclinical and clinical studies and other development requirements for product candidates.
• Risk that any product candidate will cost more to develop or may not be successfully developed and commercialized.
• Risk that sufficient capital to fund future operations will not be available on acceptable terms or at the times required.
• Inability to replicate results achieved in preclinical studies or clinical trials in any future studies or trials.
• Inability to replicate interim or early-stage results from clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials.
• Regulatory developments in the United States and foreign countries could impact clinical trial timelines and approvals.

Future Outlook

The company expects to align with the FDA on a recommended Phase 2 dose for cemsidomide in multiple myeloma by year-end 2025 and remains on track to initiate registrational development in early 2026. This next phase will evaluate cemsidomide in combination with dexamethasone in late-line MM and with a BCMA BiTE for earlier lines. Data from the CFT8919 Phase 1 trial in Greater China will inform ex-China clinical development by year-end 2025. The company also plans to advance internal and collaboration programs to key discovery milestones in 2025 and has extended its cash runway to mid-2027.

Management Comments

• "The first half of 2025 was driven by focused execution across our business with the achievement of several research milestones with our collaborators and within our internal preclinical pipeline, the advancement of cemsidomide toward label-enabling trials and continued financial discipline that resulted in extending cash runway."
• "We recently completed enrollment in the ongoing cemsidomide Phase 1 trials in multiple myeloma and non-Hodgkins lymphoma and look forward to sharing the full Phase 1 multiple myeloma data in September, which we believe further demonstrate cemsidomides best-in-class potential."
• "Our recent Type C meeting with the FDA enabled refinement of our cemsidomide registrational development plans and we remain on track to initiate registrational development in early 2026."
• "Additionally, as part of C4Ts commitment to strategic capital allocation and despite cemsidomides compelling response rates observed in non-Hodgkins lymphoma, we are prioritizing cemsidomide multiple myeloma registrational development as we believe this has the highest potential for patient impact and value creation."

Industry Context

C4 Therapeutics operates in the innovative field of targeted protein degradation (TPD), a novel therapeutic modality with the potential to address previously undruggable targets and overcome drug resistance. The company's focus on multiple myeloma and non-small cell lung cancer places it in therapeutic areas with significant unmet medical needs and evolving treatment landscapes. Cemsidomide, an IKZF1/3 degrader, aims to offer a differentiated profile compared to existing immunomodulatory drugs, while CFT8919 targets specific EGFR mutations in NSCLC that confer resistance to current standard-of-care inhibitors, aligning with the industry trend of developing precision medicines for genetically defined patient populations.

Comparison to Industry Standards

• Cemsidomide is positioned as having "best-in-class potential" among IKZF1/3 degraders due to its increased potency and selectivity, aiming to improve upon the efficacy and tolerability of existing agents in multiple myeloma.
• The observed immune T-cell activation with cemsidomide monotherapy is consistent with preclinical data and supports its potential to enhance the activity of bispecific T-cell engagers (e.g., BCMA BiTEs) in multiple myeloma, similar to how combinations like Talquetamab plus Pomalidomide have shown improved response rates (e.g., 73% ORR for Talq + Pom vs. 44% for Talq monotherapy in R/R MM patients).
• CFT8919's design to exploit an allosteric binding site and retain activity against resistance mutations (e.g., L858R-C797S) addresses a critical limitation of current orthosteric EGFR inhibitors like osimertinib, where patients with L858R mutations often experience inferior progression-free survival compared to those with Exon 19 deletions.

Stakeholder Impact

• Shareholders: Positive clinical data and extended cash runway could enhance investor confidence, while increased net losses and pipeline rationalization warrant careful monitoring.
• Multiple Myeloma Patients: Potential for a new, effective, and well-tolerated treatment option (cemsidomide), especially for late-line and potentially earlier lines of therapy.
• Non-Hodgkin's Lymphoma Patients: Development of cemsidomide for NHL is de-prioritized, potentially delaying or halting a promising treatment option for these patients.
• Non-Small Cell Lung Cancer Patients (EGFR L858R): Continued advancement of CFT8919 offers potential for a new treatment option, particularly for those with resistance mutations.
• Employees: Strategic prioritization and capital allocation may lead to a more focused workforce on core programs, potentially impacting other areas.

Next Steps

• Present data from full cemsidomide Phase 1 dose escalation in MM at the International Myeloma Society (IMS) Annual Meeting (September 17-20, 2025).
• Host an investor call to discuss cemsidomide data in MM in conjunction with the IMS presentation.
• Present data from cemsidomide Phase 1 dose escalation in NHL in Q4 2025.
• Align with the FDA on a recommended Phase 2 dose for cemsidomide in MM by year-end 2025.
• Initiate registrational development of cemsidomide in MM in early 2026.
• Evaluate cemsidomide in combination with dexamethasone in the late-line MM setting.
• Evaluate cemsidomide in combination with a BCMA BiTE for earlier lines of MM treatment.
• Present a poster analyzing cemsidomide clinical data of population pharmacokinetic and exposure-response relationships in MM and NHL at the 2025 American Conference on Pharmacometrics (ACoP 2025) on October 20, 2025.
• Utilize data from CFT8919 Phase 1 dose escalation trial in Greater China to inform ex-China clinical development by year-end 2025.
• Seek partnership for the CFT1946 BRAF program.

Key Dates

Recommendation

The company has reported compelling Phase 1 clinical data for cemsidomide in multiple myeloma, demonstrating a well-tolerated profile and strong response rates, with a clear path towards registrational development. The extension of the cash runway to mid-2027 provides financial stability. However, the company continues to incur significant net losses, and revenue from collaborations has decreased year-over-year due to milestone timing. While the clinical progress is encouraging, the company remains a clinical-stage biopharmaceutical firm with inherent development and regulatory risks. The strategic decision to prioritize multiple myeloma over non-Hodgkin's lymphoma for cemsidomide and to seek partnership for CFT1946 indicates a focused but also narrowed internal pipeline. Given the promising clinical advancements balanced against ongoing financial losses and the long development timelines typical of biotech, a "hold" recommendation is appropriate for investors who are already positioned, awaiting further clinical milestones and commercialization clarity.

Keywords

Targeted protein degradation, Multiple myeloma, Non-Hodgkin's lymphoma, Cemsidomide, IKZF1/3, EGFR L858R, CFT8919, Biopharmaceutical, Clinical trial, Oncology, Drug development, SEC filing, 8-K, BiDAC, MonoDAC